This week we talk about new treatment approvals for acute migraine, dry eye disease and schizophrenia; a new indication for Xarelto; and the Centers for Disease Control and Prevention issue an interim guidance for physicians regarding electronic cigarette, or vaping, product use-associated lung injury, or ‘EVALI’.